Radiochemical and Biological Evaluation of 99mTc-Labeling of Phthalic Acid Using 99mTc-Tricabonyl and 99mTc-Sn (II) As a Model for Potential Hazards Imaging
Journal of Molecular Imaging & Dynamics

Journal of Molecular Imaging & Dynamics
Open Access

ISSN: 2155-9937

+44 20 3868 9735

Research Article - (2016) Volume 6, Issue 2

Radiochemical and Biological Evaluation of 99mTc-Labeling of Phthalic Acid Using 99mTc-Tricabonyl and 99mTc-Sn (II) As a Model for Potential Hazards Imaging

Sanad MH1*, Saad MM2, Fouzy ASM2, Marzook F1 and Ibrahim IT1
1Labelled Compounds Department, Hot Labs Center, Atomic Energy Authority, P.O. Box 13759, Cairo, Egypt
2Food Toxin and Contaminants Department, National Research Centre, 33, Tahrir St, Dokki, Cairo, Egypt
*Corresponding Author: Sanad MH, Labelled Compounds Department, Hot Labs Center, Atomic Energy Authority, P.O. Box 13759, Cairo, Egypt, Tel: 713-500-6759 Email:


In this study, 99mTc- phthalic acid (PA) firstly, was prepared with a high radiochemical yield up to 98% that confirmed with different chromatographic techniques by using 2 mg phthalic acid, 50 μg SnCl2·2H2O as a reducing agent, in solution of pH 7 at room temperature for 30 min. Secondly, 99mTc-tricarbonyl phthalic acid was prepared under 30 min heating at 100°C. Bio distribution studies were carried out in Albino Swiss mice in which 99mTc-PA and 99mTc-tricarbonyl PA were concentrated in kidneys and intestine. This work aims to evaluation of labeled PA as a model for Potential Hazards imaging in vitro and in vivo toxicity in Albino Swiss mice.

Keywords: Phthalic acid; Labeling; Bio-distribution; Technetium- 99m; Potential hazards imaging


Phthalates are used in a wide range of common products, and are released into the environment. There is no covalent bond between the phthalates and plastics; rather, they are entangled within the plastic as a result of the manufacturing process used to make PVC articles [1]. They can be removed by exposure to heat or with organic solvents. However, people are exposed to phthalates, and most Americans tested by the Centers for Disease Control and Prevention have metabolites of multiple phthalates in their urine [2]. Phthalate exposure may be through direct use or by indirect means through leaching and general environmental contamination. Diet is believed to be the main source of di(2-ethylhexyl) phthalate (DEHP) and other phthalates in the general population. Fatty foods such as milk, butter, and meats are a major source. In studies of rodents exposed to certain phthalates, high doses have been shown to change hormone levels and cause birth defects [3]. Among healthy workers exposed to di (2-ethylhexyl) phthalate, the excretion of metabolites with the urine (o-phthalic acid: 0.21–0.31 μg/ml; n = 9) was increased as compared with non-exposed workers (o-phthalic acid: 0.19 μg/ml; n = 8) [4,5]. Patients with renal failure are exposed to di (2-ethylhexyl) phthalate during dialysis since it leaches out of the plastic tubes to a slight extent. In the body, di (2-ethylhexyl) phthalate is hydrolyzed mainly to o-phthalic acid, which is detected in the serum and dialysate and is excreted unchanged in the urine [6,7]. Technetium-99m (99mTc) is the radionuclide of choice for diagnostic imaging due to its ideal nuclear properties (Eγ = 140 keV, T1/2 = 6 h, no β-emission) and availability from a 99Mo/ 99mTc generator [8,9]. Although the previous imaging methods using stannous chloride dihydrate as reducing agent or others was considered simple and rapid labeling method with the 99mTc isotope that have been developed for clinical applications but its disadvantage in less stability in saline or serum. So 99mTc-tricarbonyl precursor was developed to overcome this problem which considered more stable and can label many compounds by on bond onle where other methods need four bond to label any compound [10,11]. Phithalic acid was labeled by 99mTc-tricarbonyl precursor to give accurate ratio of the concentrated of complex in different organs and that give us complete information about this compound than other method which is more difficult and not give this results. Factors affecting the labeling yield of 99mTc-phthalic acid complex (Figure 1) and biological distribution in Swiss Albino mice (25- 30 gm) were studied in detail. The radiochemical yield of the complex was determined by paper chromatography, paper electrophoresis and High Performance Liquid Chromatography (HPLC).


Figure 1: Chemical structure of phthalic acid.

Materials and Methods

Materials and instrumentation

Phthalic acid was purchased from Sigma Chemical Company, USA., Other chemicals were purchased from Merck and they were reactive grade reagent. Purged deoxygenated bidistilled water were used during all experiment. Electrophoresis apparatus model EC- 3000 p-series programmable (E.C. Apparatus Corporation) power and chamber supply units using cellulose acetate strips (Albany, Orion Research, USA) was used. A well-type NaI scintillation γ-Counter model Scalar Ratemeter SR7 (Nuclear Enterprises Ltd., USA) was also used for radioactive measurement.

Preparation of stock solution of SnCl2.2H2O

One hundred and nintymilligramsof Tin (II) chloride dihydrate (stannous chloride dihydrate) were completely dissolved in 0.5 ml Conc. HCl (25%) by heating on a hot plate then the volume was completed to 10 ml by water. Each ml containing 19 mg of stannous chloride dehydrate was equivalent to 10 mg of tin (II). By dilution, different concentrations of SnCl2.2H2O (38 to 760 μg ml-1) were prepared. Each concentration was flushed with nitrogen gas for 15 min and kept at -20°C till use. These concentrations were equivalent to 20-400 μg ml-1of Tin (II). Selection the optimum concentration of Sn (II) was done by examination the effect of each concentration on the labeling efficacy. Five hundred micro liter of each concentration (from 10 to 200 μg) was used to prepare the labeled mixture.

Labeling of 99mTc-phthalic acid

At the optimum amount of Sn (II) (50 μg), optimum pH (7) and optimum duration 30 min, different concentrations of phthalic acid (4 - 40 mg ml-1 water) were examined to select the optimum concentration to be labeled. Two hundred and fifty microliters of each concentration (containing from 1-10 mg) was transferred to a penicillin vial and evacuated. The previously prepared SnCl2.2H2O (500 μl, 50ug Sn II) solution was added and the pH of the mixture was adjusted to 7. The volume of the mixture was finally adjusted to one ml by water. One ml of freshly eluted 99mTcO4-(200-400 MBq) was added to the above mixture. The reaction mixture was vigorously shaken and allowed to react at room temperature for sufficient time (30 min) to complete the reaction. The proposed structure (Figure 2) of the 99mTc-phthalic acid complex via. reaction of phthalic acid with 99mTc-pertechnetate in the optimum conditions made the oxidation state of 99mTc changed from +7 into +5 to form a complex with two molecules of phthalic acid. 99mTcphthalic acid complex coordinated as a Tc (V) oxocore, leading to the formation of a complex in which a TcO3+ core existed. This complex formed by two molecules with one another where two (COOH) from every molecule shared to form a complex of 99mTc-phthalic acid.


Figure 2: Proposed structure of 99mTc- PA.

Synthesis of 99mTc-tricarbonyl precursor

99mTc-tricarbonyl precursor was prepared by the addition of 1 ml of 99mTc-pertechnetate (99mTcO4 –, 740 – 3700 MBq) to a penicillin vial with 7.15 mg sodium carbonate, 4.5 mg sodium boranocarbonate, 2.85 mg sodium tetraborate and 8.5 mg sodium tartrate. After heating for 30 min in a boiling water bath and cooling, the basic solution (pH = 11) was brought to room temperature. The labeling yield and stability of the [99mTc (CO)3 (H2O)3]+ ion were determined using (RP-HPLC). The 99mTc-tricarbonyl precursor was successfully prepared with a high radiochemical yield (> 95%) (Figures 3-6) [12-14].


Figure 3: Proposed structure of 99mTc-tricarbonyl PA.


Figure 4: Electrophoresis radio chromatogram of 99m Tc- phthalic acid.


Figure 5: HPLC of 99mTc- phthalic acid complex.


Figure 6: HPLC radiochromatogram of [Tc(CO)3(H2O)3]+ precursor, pH = 11, flow rate 0.6 ml/min, Rt = 4.5 min for [Tc(CO)3(H2O)3]+ , Rt = 11.44 min for free 99mTcO4 – using 0.22 μm millipore filtration to eliminate unknown radiochemical impurities.

Radio labeling with 99mTc-tricarbonyl precursor

The tricabonyl complex (99mTc (CO)3 PA) was performed by adding 1 ml of the prepared tricabonyl ion to 2 mg PA (10 mg 5/ml in DMF), at room temperature. Then the reaction vial was heated to100°C for 30 min. After cooling down to room temperature (25 ± 1°C), labeling yields were checked by radio-HPLC (Figure 7). According to the previously published results [12-15],99mTcO4- is reduced from the oxidation state +7 into +1 by forming 99mTc-tricarbonyl precursor. Therefore, 99mTc- (CO)3 PA was formed by two bonded (OH-) groups in the IDA part of the molecule. This complex is confirmed by HPLC results.


Figure 7: 99mTc-tricarbonyl PA (>99%) at pH = 7.

Labeling verification

The radiochemical yield and stability of 99mTc-phthalic acid were determined by paper chromatography method (PC), electrophoresis condition and High Performance Liquid Chromatography (HPLC). But 99mTc-(CO)3 PA was confirmed by HPLC only.

Paper chromatography of 99mTc-phthalic acid

Radiochemical yield of 99mTc-phthalic acid was checked by paper chromatography method in which, the reaction product was spotted on ascending paper chromatography strips (10 × 1.5 cm). Free 99mTcO4- used in the preparation was determined using acetone as the mobile phase. Reduced hydrolyzed technetium was determined by using ethanol: water: ammonium hydroxide mixture (2:5:1) as the mobile phase. After complete development, the strips were dried then cut into 0.5cm pieces and counted in a well-type γ-scintillation counter.

Electrophoresis conditions of 99mTc-phthalic acid

Electrophoresis was done with EC-3000 p-series programmable (E.C. Apparatus Corporation) power and chamber supply units using cellulose acetate strips. The strips were moistened with 0.05 M phosphate buffer pH 7.2 ± 0.2 and then were introduced in the chamber. Samples (5μl) were applied at a distance of 10 cm from the cathode with standing time for one and half hours and the applied voltage (300 v) were continued. Developed strips were dried and cut into 1 cm segments and counted by a well-typeNal scintillation counter (Figure 4).

HPLC analysis for 99mTc-phthalic acid

A High-Performance Liquid Chromatography (HPLC) was established for the simultaneous determination of phthalic acid. The mobile phase was methanol-water-ammonium acetate-acetic acid buffer (pH 4.70) (5/40/55/, v/v/v) at a flow rate of 0.2 ml min-1, and UV absorption wavelength at 254 nm. Five microliters of the reaction mixture was injected into the column (RP-C18-250 mm × 3 mm, 5μm, LiChrosorb) built in HPLC Shimadzu model which consisted of pumps LC-9A, Rheohydron injector. Fractions of 20 ml were collected separately using a fraction collector up to 20 ml and measured in a welltype- γ-scintillation counter (Figure 5) [16].

HPLC for 99mTc-(CO)3 PA

A 10 μl aliquot of the 99mTc-(CO)3 PA reaction mixture was injected into RP18 (Lichrosorb, 250 mm x 3 mm, 5 μm) column. The mobile phase consisted of methanol (solvent B) and 0.05 M TEAP (triethyl ammonium phosphate) (solvent A). Gradient system was made up following an isocratic elution (100% A) for the first 0~5 min; a linear gradient of 75% A/25% B to 100% A/0% B was obtained for 5~8 min; a linear gradient of 66% A/34%, B to 75%, A/25%, B was obtained for 8~11 min; a linear gradient of 0% A/100%, B to 66%, A/34%, B was obtained for 11~22 min; and an isocratic elution (100% B) was obtained for 22~25 min. The flow rate was 0.6 ml/min (Figure 7) [12-14].

In-vitro stability test of 99mTc-PA and 99mTc-tricarbonyl PA.

In-vitro stability of 99mTc- phthalic acid was studied in order to determine the suitable time for injection to avoid the formation of the undesired products that result from the radiolysis of complex. These undesired radioactive products might be accumulated in non-target organs. The results of stability showed that the 99mTc-phthalic acid was stable for 24 hours at 37°C as determined by (PC) sheets. Also, 99mTctricarbonyl PA remained stable during 24 h that can be determined by HPLC [12-14].

Stability in Serum

The stability in rat serum of purified 99mTc-tricarbonyl PA and 99mTcphthalic acid was determined by mixing 0.1 ml of 99mTc-tricarbonyl PA or 99mTc-phthalic acid solution with 0.9 ml rat serum and kept at 37°C. At time intervals, the stability was assayed using HPLC and PC techniques [12-14].

Animal Studies

The study was approved by the animal ethics committee, Labeled Compound Department, and was in accordance with the guidelines set out by the Egyptian Atomic Energy Authority. The animals, normal Swiss Albino mice (30-35 gm), were intravenously injected with 100 μl (3.3 mg kg-1 body weight, 100–150 MBq) of sterile 99mTc-phthalic acid and kept alive in metabolic cage for different intervals of time under normal conditions. For quantitative determination of organ distribution, five mice were used for each experiment and the mice were sacrificed at different time post-injection. Samples of fresh blood, bone and muscle were collected in pre-weighed vials and measured. The different organs were removed, counted and compared to a standard solution of the labeled PA. The average percent values of the administrated percent injected dose per gram (% ID/organ ± SD) were calculated. Blood, bone and muscles were assumed to be 7, 10 and 40%, respectively, of the total body weight [17].

Statistical Analysis

Data were evaluated with one way analysis of variance test (name of used program). All the results were observed as mean ± SEM of five replicates. The level of significance was set at p<0.05.

Results and Discussion

Verification of labeling procedure

In case of ascending paper chromatographic method, acetone was used as the developing solvent, free 99mTcO4-moved with the solvent front (Rf=1), while 99mTc- phthalic acid and reduced hydrolyzed technetium (colloid) remained at the point of spotting. After developing with the mixture of ethanol: water: ammonium hydroxide, reduced hydrolyzed technetium remains at the origin (Rf = 0) while other species migrate with the solvent front (Rf =1). The radiochemical purity was determined by subtracting the sum of the percent of reduced hydrolyzed technetium and free pertechnetate from 100%. The radiochemical yield was calculated from the mean value of five experiments.

The paper electrophoresis pattern revealed that 99mTc-phthalic acid complex moved towards the anode with 2.8 cm distance (Figure 4). Whereas, 99mTcO4- moved towards the anode with 12 cm distance suggesting that it had a high negative charge. Radioactivity yield (%) = Peak activity of the 99mTc- phthalic acid × 100/Total activity.

HPLC chromatogram is presented in (Figure 5). Three sharp peaks was obtained, one at 4.5 min retention time, which corresponded to 99mTcO4- , second one at 15.2 min, which corresponded to the UV signal of phthalic acid. While the last peak was observed at 15.6 min which revealed to 99mTc-phthalic acid.

Factors effecting on the labeling yield

Effect of SnCl2.2H2O concentration: The effect of SnCl2.2H2O amount in the reaction mixture on the radiochemical yield of phthalic acid is illustrated in (Figure 8). At 10 μg of Sn (II), the labeling yield of 99mTc-phthalic acid was low (66%) due to the fact that SnCl2.2H2O concentration was insufficient to reduce all pertechnetate so 20% of 99mTcO4-remained in the solution. The labeling yield significantly increased by increasing the amount of SnCl2.2H2O from 10 to 50 μg (optimum amount), at which a maximum labeling yield of 98% was obtained. By increasing the amount of SnCl2.2H2O, above 50 μg, the labeling yield decreased again because the excess SnCl2.2H2O was converted to colloid (55% at 200 μg SnCl2.2H2O). This finding could be interpreted by the consumption most of the ligand molecules in the formation of complexes. Subsequently the pertechnetate was reduced to insoluble technetium (IV) TcO2. × H2O in the absence of ligand [18-20]. In other explanation, this decrease attributed to the fact that the excess amount of stannous chloride led to the formation of stannous hydroxide colloid Sn(OH)-3 in basic medium [21-23] as the very high Sn (II) concentration increased the reduction reaction rate to colloid formation and it became more competitive with respect to the complexation reaction thus decreasing the labeling yields.


Figure 8: Effect of SnCl2.2H2O amount on the radiochemical yield % of 99mTcphthalic acid.

Effect of the amount of phthalic acid: At constant conditions of Sn II amount (50 μg), pH (7) and duration (30 min), different amounts of phthalic acid were used (Figure 9). Using 1 mg of phthalic acid gave 80% radiochemical yieldin99mTc-phthalic acid complex. Whereas, 98% labeling yield was obtained by using 2 mg phthalic acid instead of 1 mg. Surprisingly, this yield did not change by increasing the amount of phthalicacideven at 10 mg. Similar findings were observed in case of tricabonyl and levosalbutamollebeling [24].


Figure 9: Percent radiochemical yield of 99mTc- phthalic acid as a function of substrate amount.

Effect of pH of the reaction mixture: Labeling of phthalic acid affected dramatically by changes in pH (4-12) (Figure 10). The optimum pH was found to be in basic medium (pH=7) that gave the maximum radio-chemical yield of 98%. This observation agreed with [25] who found that the base medium was the optimum level to label muscarinic receptors in rats. The radiochemical yield of 99mTc-phthalic acid complex in acidic medium (pH 4) was low (47%) with the appearance of free pertechnetate as predominant species 20%. The percentage of 99mTc-phthalic acid increased gradually by the increase of pH up to 7 which gave the maximum radiochemical yield. Increasing the pH of the reaction medium above pH 7 (8 to 12) decreased the radiochemical yield of 99mTc- phthalic acid from 88% to 55% respectively [26-28].


Figure 10: Effect of pH on the radiochemical yield % of 99mTc- phthalic acid.

Effect of reaction time: Different duration time (1-120 min) was examined for its efficiency in radiochemical labeling (Figure 11). The radiochemical yield of 99mTc- phthalic acid complexe at 1 min post labeling was low (77%). Half an hour was the optimum duration gave the best yield (98%) which kept stable even after 120 min. Similar work done on 99mTc-cefprozil which increased with time until reaching its maximum value of 97.5% at 30 min [29].


Figure 11: 99mTc- phthalic acid yields vs. reaction time.

In-vitro Stability Test Of 99mTc-PA And 99mTc-tricarbonyl PA

As illustrated in (Figure 12). The 99mTc-phthalic acid complex considered stable during 24 h resulted in a small release of radioactivity as determined by (PC) sheets which decreased from 98 ± 0.11% to 95 ± 0.43% (Figures 13 and 14) shows that 99mTc-tricarbonyl PA remained stable during 24 h and decayed from > 99% to 96% as detected by RPHPLC [12-14].


Figure 12: In-vitro stability of 99mTc- phthalic acid at optimum conditions.


Figure 13: Stability in serum of 99mTc- phthalic acid at optimum conditions.


Figure 14: In-vitro stability of 99mTc-tricarbonyl PA (96%) at optimum condition.

Stability in Serum

The stability of 99mTc- phthalic acid in normal serum at 37°C is as illustrated in (Figure 13) with a small release of radioactivity as determined by (PC) sheets which decreased from 98 ± 0.11% to 89 ± 0.22%. The stability in serum of 99mTc-tricarbonyl showed that small release of radioactivity (n = 5 experiments) which decreased from >99% to 94% (Figure 15) [30-33].


Figure 15: In-vitro stability of 99mTc-tricarbonyl PA in serum at 37ºC.


(Table 1) shows the in vivo behavior of the 99mTc- phthalic acid in mice at 30, 60, 120, and 240 min post intravenous injection. The bio distribution of 99mTc- phthalic acid in important body organs and fluids was evaluated. All radioactivity levels are expressed as average percentinjected dose per organ (%ID/ total organ in the most relevant organs for the complex ± S. D) [34-37]. All organ like blood, heart, lung, stomach, spleen, muscle and bone were declined with time from 30 min up to 4 h. The uptake within the kidneys were increased from 5.90% at 30 min post injection to 15.80% at 2 h post injection which declined to 6.12% at 4 h post injection with increasing of urine uptake from 4.30 at 30 min to 37.90% at 4 h post injection. The uptake in liver increased from 3.60% at 30 min post injection to 6.00 at 2 h post injection that declined to 2.10% at 4 h post injection. Also, the uptake of intestine were increased from 15.19% at 30 min post injection to 33.00% at 2 h post injection which decline to 14.55% at 4 h post injection [38- 40]. Also (Table 2) of 99mTc-tricarbonyl phthalic acid shows the same biodistribution without differences than 99mTc- phthalic acid. So, this complex was excreated through kidneys and intestine that is important to follow this compound in human body as a toxic substance [41-45].

Organs and Body fluids % Injected dose/organs and body fluids at different time post injection
30 min 1 h 2 h 4 h
Liver 3.60 ± 0.22 4.90 ± 0.10 6.00 ± 0.19 2.10 ± 0.66
Urine 4.30 ± 0.12 5.27 ± 0.22 13.00 ± 1.10 37.90 ± 0.50
Kidneys 5.90 ± 0.80 9.75 ± 0.15 15.80 ± 0.40 6.12 ± 0.13
Blood 8.27 ± 1.00 2.90 ± 0.80 1.10 ± 0.40 0.90 ± 0.01
Heart 1.10 ± 0.007 0.95 ± 0.001 0.70 ± 0.005 0.50 ± 0.003
Lung 0.90 ± 0.001 0.81 ± 0.003 0.60 ± 0.10 0.40 ± 0.0001
Stomach 1.60 ± 0.11 1.10 ± 0.02 0.90 ± 0.20 0.77 ± 0.001
Intestine 15.19 ± 0.09 22.50 ± 1.00 33.00 ± 1.11 14.55 ± 0.09
Spleen 1.10 ± 0.20 0.90 ± 0.001 0.80 ± 0.002 0.50 ± 0.002
Muscle 1.20 ± 0.002 1.11 ± 0.07 0.95 ± 0.06 0.60 ± 0.001
Bone 1.12 ± 0.10 1.00 ± 0.04 0.90 ± 0.07 0.60 ± 0.002
SD (mean of five experiments)  ±  Mean

Table 1: Bio-distribution of 99mTc-phthalic acid in mice at different post-injection times.

Organs and Body fluids % Injected dose /organs & body fluid at different time post injection
30 min 1 h 2 h 4 h
Liver 3.00 ± 0.21 7.80 ± 0.11 9.00 ± 0.17 4.90 ± 0.33
Urine 3.20 ± 0.19 6.29 ± 0.24 16.00 ± 0.90 39.95 ± 0.44
Kidneys 7.10 ± 0.22 12.68 ± 0.13 19.60 ± 0.20 8.13 ± 0.11
Blood 9.5 ± 0.77 3.11 ± 0.60 1.30 ± 0.22 0.80 ± 0.31
Heart 1.12 ± 0.01 0.95 ± 0.002 0.80 ± 0.003 0.60 ± 0.001
Lung 0.96 ± 0.002 0.81 ± 0.001 0.60 ± 0.001 0.50 ± 0.001
Stomach 1.10 ± 0.01 1.20 ± 0.001 0.96 ± 0.002 0.81 ± 0.002
Intestine 13.15 ± 0.01 19.90 ± 1.11 35.00 ± 0.15 16.00 ± 0.001
Spleen 1.00 ± 0.10 0.98 ± 0.002 0.91 ± 0.001 0.80 ± 0.001
Muscle 0.90 ± 0.001 1.00 ± 0.01 0.90 ± 0.002 0.80 ± 0.002
Bone 1.00 ± 0.01 1.10 ± 0.001 0.98 ± 0.002 0.80 ± 0.001
SD (mean of five experiments)  ±  Mean

Table 2: Bio-distribution of 99mTc-tricarbony phthalic acid in mice at different postinjection times.


Phthalic acid esters (phthalates) are used as plasticizers in numerous consumer products, commodities, and building materials. Consequently, phthalates are found in human residential and occupational environments in high concentrations, both in air and in dust. Phthalates are also ubiquitous food and environmental contaminants [46]. An increasing number of studies sampling human urine reveal the ubiquitous phthalate exposure of consumers in industrialized countries. At the same time, recent toxicological studies have demonstrated the potential of the most important phthalates to disturb the human hormonal system and human sexual development and reproduction. Additionally, phthalates are suspected to trigger asthma and dermal diseases in children [47]. The metabolism of phthalates first produces phthalate monoesters, which can be metabolized further to oxidative products [48]. Many metabolites are glucuronidated and excreted in the urine and feces [49]. On this study, the labeled phthalic acid was studied in mice at 30,60, 120, and 240 min post intravenous injection. The biodistribution of labeled phthalic acid shows that it was excreated through kidneys and intestine.


Phthalic acid complex was labeled easily by tow methods firsly using SnCl2.2H2O as a reducing agent and 30 min reaction time with a labeling yield of 98 ± 0.11% secondly by tricarbonyl core to give > 99% radiochemical yield. Its stability in saline and serum was studied in both cases. Depending on the data obtained from the biodistribution in case of 99mTc- phthalic acid and 99mTc-tricarbonyl PA. It was stated that this complex was concentrated in kidneys and intestine, on the other hand labeling of phthalic acid considered a new strategy to analyse phthalate as an end hydrolysis product of phthalate in the biological systems.


We especially thank Prof. Dr. N. Farouk, Prof. Dr. E. Borai, Prof. Dr. K. F. Wanis and Prof. Dr. Ahmed Abdelmohty for their excellent work and kindly help for what we have done in the paper.


  1. Randi JB, Karin CLC, Antonia MC, Jane AH, Geir Håland, et al. (2013) Urinary biomarkers for phthalates associated with asthma in Norwegian children. Environ Health Perspect 121: 251-256
  2. Third National Report on Human Exposure to Environmental Chemicals (2005) at the Wayback Machine.
  3. Rettenmeier AW (1994) Untersuchungenzur Belastung und Beanspruchung von Normalpersonen und beruflichexponierten Arbeitnehmerndurch den Weichmacher Di-(2-ethylhexyl) phthalate (Investigations of the level of external and internal exposure of normal persons and occupationally exposed workers to the plasticizer di(2-ethylhexyl) phthalate) (German). Abschlußberichtfür das Umweltministerium Baden-Württemberg, InstitutfürArbeits- und Sozialmedizin, Universität Tübingen.
  4. Rettenmeier AW (1995) Untersuchungenzur Belastung und Beanspruchung von Normalpersonen und beruflichexponierten Arbeitnehmerndurch den Weichmacher Di-(2-ethylhexyl) phthalate (Investigations of the level of external and internal exposure of normal persons and occupationally exposed workers to the plasticizer di(2-ethylhexyl) phthalate) (German). in: Landesanstalt.
  5. Mettang T, Alscher DM, Pauli-Magnus C, Dunst R, Kuhlmann U, et al. (1999) Phthalic acid is the main metabolite of the plasticizer di(2-ethylhexyl) phthalate in peritoneal dialysis patients. Adv Perit Dial 15: 229 -232.
  6. Mettang T, Fischer FP, Dunst R, Kuhlmann U, Rettenmeier AW (1997) Plasticizers in renal failure: Aspects of metabolism and toxicity. Perit Dial Int 17: S31-S36.
  7. Wong DF, Gründer G, Brasic JR (2007) Brain imaging research: does the science serve clinical practice? Int Rev Psychiatry 19: 541-558.
  8. EL-GhanyE A, Amin AM, EL-Sayed AS, EL-Kolaly MT, Abdel-Gelil F (2005) Radiochemical and biological characteristics of 99mTc-piroxicam for scintigraphy of inflammatory lesions. J Radioanal Nucl Chem 266: 125-130.
  9. Technetium-99m radiopharmaceuticals: Manufacture of kits (2008) IAEA Publications.
  10. Alberto R, Schibli R, Egli A, Schubiger AP (1998) A novel organometallic aqua complex of technetium for the labeling of biomolecules: synthesis of [99mTc(OH2)(CO)3]+ from [99mTcO4]− in aqueous solution and its reaction with a bifunctional ligand. J Am Chem Soc 120: 7987-7988.
  11. Sanad M, Borai E (2015) Comparative biological evaluation between 99mTc tricabonyl and 99mTc-Sn(II) levosalbutamol as a β 2-adrenoceptor agonist. Radiochim Acta 103: 879-891.
  12. Sanad M, Shweeta H (2015) Preparation and Bio-evaluation of 99mTc-carbonyl complex of ursodeoxycholic acid for heptobiliary imaging. J Mol Imag Dynamic 5: 119. doi:10.4172/2155-9937.1000119
  13. Sanad MH, El-Bayoumy ASA, Alhussein AI (2016) Comparative biological evaluation between 99mTc(CO)3 and 99mTc-Sn (II) complexes of novel quinoline derivative: a promising infection radiotracer. J Radioanal Nucl Chem.
  14. El-Tawoosy M (2013) Preparation and biological distribution of 99mTc-cefazolin complex, a novel agent for detecting sites of infection, J Radioanal Nucl Chem 1215.
  15. Na Y, Jun-Qin Q, Hong-Zhen L (2012) Simultaneous determination of nine related substances in p-phthalic acid residue by RP-HPLC. J Chromatogr Sci 50: 410-413.
  16. Liu HR, Zhao RR, Jiao XY, Wang YY, Fu M (2002) Relationship of myocardial remodeling to the genesis of serum autoantibodies to cardiac beta-1-adrenoceptors and muscarinic type 2 acetylcholine receptors in rats. J Am Coll Cardiol 39: 1866.
  17. Srivastava SC, Richards P (1983) Technetium-labeled compounds. In: Rayudu GVS (ed) Radiotracers for medical applications, CRC series in radiotracers in biology and medicine. CRC Press, Boca Raton 107-185.
  18. Wardell JL (1994) Tin: Inorganic chemistry. In: King RB (ed) Encyclopedia of inorganic chemistry. Wiley New York. 8: 415.
  19. Sanad MH, Borai EH (2015) Comparative biological evaluation between 99mTc tricarbonyl and 99mTc-Sn (II) levosalbutamolas a β2-adrenoceptor agonist. Journal of Radiochim Acta.
  20. Sanad MH, Borai EH (2014). Performance characteristics of bio-distribution of 99mTc-cefprozil for in vivo infection imaging. Journal of Analytical Science and Technology (JAST) 5: 32.
  21. Amin A, Sanad M, Abd-Elhaliem S (2013) Radiochemical and Biological Characterization of 99mTc-Piracetam for Brain Imaging. Radiochemistry 55: 624-628.
  22. James C (2002) Cellular roles of DNA topoisomerases: A molecular perspective. Nature Reviews Molecular Cell Biology 3: 430-440.
  23. John L (1998) Investigating the biological functions of DNA topoisomerases in eukaryotic cells. Biochim Biophys Acta 1400: 63-81.
  24. El-Kawy OA, Sanad MH, Marzook F (2016) 99mTc-Mesalamine as potential agent for diagnosis and monitoring of ulcerative colitis: labelling, characterization and biological evaluation. J Radioanal Nucl Chem 308: 279-286.
  25. Sanad MH, Ibrahim IT (2013) Radiodiagnosis of peptic ulcer with technetium-99m-pantoprazole. J. Radiochemistry 55: 341.
  26. Sanad MH (2013) Labeling and biological evaluation of 99mTc-azithromycin for infective inflammation diagnosis. J. Radiochemistry 55: 539.
  27. Sanad MH (2014) Novel radiochemical and biological characterization of 99mTc-histamine as a model for brain imaging. JAST 5: 23.
  28. Motaleb MA, El-Said H, Abdallah M, M. Atefb (2012) Synthesis and evaluation of 99mTc-NIDA and 99mTc-DMIDA complexes for hepatobiliary imaging. Journal of Radiochemistry 54: 501.
  29. Wormuth M, Scheringer M, Vollenweider M, Hungerbühler K (2006) Risk Anal Institute for Chemical and Bioengineering. Switzerland. 26(3):803-824.
  30. ATSDR (2002) Toxicological profile for Di(2-ethylhexyl)phthalate (DEHP). Agency for Toxic Substances and Disease Registry. Atlanta, GA.
  31. ATSDR (2001) Toxicological profile for di-n-butyl phthalate (DBP). Agency for Toxic Substances and Disease Registry; Atlanta, GA.
  32. Sanad MH (2013) Labeling of omeprazole with technetium-99m for diagnosis of stomach. J. Radiochemistry 55: 605-609.
  33. Sanad MH, Ibrahim I (2015) Radiodiagnosis of peptic ulcer with technetium-99m labeled rabeprazole. J. Radiochemistry 57: 425-430.
  34. Moustapha M, Motaleb M, Sanad MH (2016) Synthesis and biological evaluation of 99mTc-labetalol for 1-adrenoceptor-mediated cardiac imaging. J. Radioanal Nucl Chem 309:511-516.
  35. Motaleb MA, Adli ASA, El-Tawoosy M, Sanad MH, AbdAllahb M (2016) An easy and effective method for synthesis and radiolabelling of risedronate as a model for bone imaging. J. Label Compd. Radiopharm 59, 157-163.
  36. Sanad MH, Sallam KM, Marzook FA, Abd-Elhaliem SM (2016) Radioiodination and biological evaluation of candesartan as a tracer for cardiovascular disorder detection. J. Label Compd. Radiopharm 59: 484-491.
  37. Bonte FJ, Hynan L, Harris TS, White CL (2011) 99mT -HMPAO brain blood flow imaging in the dementias with histopathologic correlation in 73 patients. J Mol Imaging.
  38. Brooks DJ (2005) Positron emission tomography and single-photon emission computed tomography in central nervous system drug development. Neuro Rx 2(2): 226-236.
  39. Syed QS, Mohammad RK, Syed MA (2011) Radiosynthesis of 99mTc (CO)3-clinafloxacin dithiocarbamate and its biological evaluation as a potential staphylococcus aureus infection radiotracer. Nucl Med Mol Imaging 45: 248-254.
  40. Neirinckx RD, Canning LR, Piper IM, Nowotnik DP, Pickett RD, et al. (1987) 99mT – D,L HMPAO a new radiopharmaceutical for SPECT imaging of regional cerebral blood flow, J Nucl Med 28: 191-202.
  41. Walovitch RC, Hill TC, Garrity ST, Cheesman EH, Burgess BA, et al (1989) Characterization of 99mTc-l,l-ECD for brain perfusion imaging. Part 1: Pharmacology of 99mTc-ECD in non-human primates. J Nucl Med 30: 1892-1901.
  42. Chang C, Shiau Y, Wang J, Ho S, Kao A (2002) Abnormal regional cerebral blood flow on 99mTc ECD brain SPECT in patients with primary Sjögren's syndrome and normal findings on brain magnetic resonance imaging. Ann Rheum Dis 61: 774-778.
  43. Devous MD (1998) In: Murray IPC, Ell PJ Nuclear medicine in clinical diagnosis and treatment (2ndedn). McGraw- Hill, New York. 631-649.
  44. Dickerson BC, Sperling RA (2005) Neuroimaging biomarkers for clinical trials of disease-modifying therapies in Alzheimer's disease. NeuroRx 2(2): 348-360.
  45. Eckert T, Eidelberg D (2005) Neuroimaging and therapeutics in movement disorders. NeuroRx 2(2): 361-371.
  46. Heinz A, Jones DW, Raedler T, Coppola R, Knable MB, et al. (2000) Neuropharmacological studies with SPECT in neuropsychiatric disorders. Nucl Med Biol 27(7): 677-682.
  47. Kuzniecky RI (2005) Neuroimaging of epilepsy: Therapeutic implications. NeuroRx 2(2): 384-393.
  48. Suhara T, Sudo Y, Yoshida K, Okubo Y, Fukuda H, et al. (1998) Novel radioiodinated sibutramine and fluoxetine. Lancet 351: 332-335.
Citation: Sanad MH, Saad MM, Fouzy ASM, Marzook F, Ibrahim IT (2016) Radiochemical and Biological Evaluation of 99mTc-Labeling of Phthalic Acid Using 99mTc-Tricabonyl and 99mTc-Sn (II) As a Model for Potential Hazards Imaging. J Mol Imag Dynamic 6:126.

Copyright: © 2016 Sanad MH, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.